1. AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus - A comprehensive review. Clin Rev Allergy Immunol. 2013;45:331–79.
2. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infect Dis Ther. 2016;5:271–98.
3.Hall CB,Long CE,Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults.Clin Infect Dis 2001;33:792-796.
4.Couch RB,Englund JA,Whimbey E.Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med,1997;102:2-9 discussion 25-6.
5. Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D, et al.Respiratory Syncytial Virus Infection in Patients with Hematological Diseases:Single-Center Study and Review of the Literature. Clin Infect Dis. 2008;46:402–12.
6. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus
infection in recipients of allogeneic stem-cell transplantation: a retrospective
study of the incidence, clinical features, and outcome. Transplantation. 2009;
88:1222–6.
7.Lehners N, Schnitzler P, Geis S, Puthenparambil J, Benz MA, Alber B, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48:1548–53.
8.Kelly SG, Metzger K, Bolon MK, Silkaitis C, Mielnicki M, Cullen J, et al. Respiratory syncytial virus outbreak on an adult stem cell transplant unit. Am J Infect Control. 2016;44:1022–6.
9.Inkster T, Ferguson K, Edwardson A, Gunson R, Soutar R. Consecutive yearly
outbreaks of respiratory syncytial virus in a haemato-oncology ward and efficacy of infection control measures. J Hosp Infect. 2017;96:353–9.
10.Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European conference on infections in leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56: 258–66.
11.Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:1–3.
12.Shah Jharna N,Chemaly Roy F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.[J]. Blood,2011,117:2755-63.
13. Aslan T,Fassas A B,Desikan R,Siegel D,Munshi N,Mehta J,Singhal S,Barlogie B,Anaissie E. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy.[J]. Bone marrow transplantation,1999,24:505-9.
14.Anaissie Elias J,Mahfouz Tahsine H,Aslan Turan,Pouli Anastasia,Desikan Rahman,Fassas Athanasios,Barlogie Bart. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management.[J]. Blood,2004,103:1611-17.
15.Jensen Tomas Ostergaard,Stelzer-Braid Sacha,Willenborg Christiana,Cheung Carol,Andresen David,Rawlinson William,Clezy Kate. Outbreak of respiratory syncytial virus (RSV) infection in immunocompromised adults on a hematology ward.[J]. Journal of medical virology,2016,88:1827-31.
16.Hirsch HH,Martino R,Ward KN,Boeckh M,Einsele H,Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013;56:258-266.
17.Tomblyn M,Chiller T,Einsele H,Gress R,Sepkowitz K,Storek J,Wingard J R,Young J-A H,Boeckh M J. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface.[J]. Bone marrow transplantation, 2009,15:1143-238.
18.Kramer Axel,Schwebke Ingeborg,Kampf Günter.How long do nosocomial pathogens persist on inanimate surfaces?[J]. BMC infectious diseases,2006,6:130.
19.Lehners N,Tabatabai J,Prifert C,Wedde M,Puthenparambil J,Weissbrich B,et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PloS One,2016;11:1-17.
20.Von Lilienfeld-Toal M,Berger A,Christopeit M,Hentrich M,Heussel CP,et al.Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.Eur J Cancer.2016;67:200-12.
21.French CE,Mckenzie BC,Coope C,Rajanaidu S,Paranthaman K,Pebody R,et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events:A systematic review. Influenza Other Respi.Viruses. 2016;10:268-90.
22.Shachor-Meyouhas Y,Zaidman I,Kra-Oz Z,Arad-Cohen N,Kassis,I.Detection,control,and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department.J Pediatric Hematology Oncology.2013;35:124-8.
23.Terletskaia-Ladwig E,Enders G,Schalasta G,Enders M.Defining the timing of respiratory syncytial virus(RSV) outbreaks:an epidemiological study:BMC Infect Dis.2005;5:20.